Recent studies demonstrated that CD19/CD133 tandem CAR T induces robust cytotoxicity against CD19+ CD133+ and CD19− CD133+ B-cell lines, suggesting CD133 a promising target MLL-R ALL immunotherapy [24]. The gene discussed is PROM1; the disease is acute lymphoblastic leukemia.